Papillary squamotransitional cell carcinoma of the uterine cervix: A rare case report.

Key Clinical Message: Although papillary squamotransitional cell carcinoma is an uncommon variant of cervical squamous cell carcinoma, due to the complex papillary structure and the challenge in detecting stromal invasion, its timely diagnosis and treatment are very important. Abstract: Papillary squamotransitional cell carcinoma (PSTCC) is extremely rare and presents with a spectrum of morphologies. PSTCC may present as an in situ tumor with or without an invasion, but usually, it displays both features. Here we report a 60-year-old woman, diagnosed with PSTCC of the uterine cervix.

Comparison of Ki67 index and P16 expression in different grades of cervical squamous intraepithelial lesions.

Background: the assessment of P16 expression and Ki-67 proliferative index is now proposed as an adjunct test for the diagnosis of high-risk precursor lesions for cervical cancer. The aim of the present study was to elucidate the quality expression of P16 and quantification Ki-67 index in different types of cervical intraepithelial neoplasia and also to determine the cutoff for Ki67 index to predict the severity of CIN lesions. Methods: This cross-sectional study was conducted on patients with colposcopic indication. Selected samples with different CIN grades were examined for P16 and Ki-67 index by immunohistochemical (IHC) methods. Results: All LSIL (CIN I) cases were negative for P16, while in 58.7% of HSIL cases (CIN 2/3), P16 was positive. The mean Ki67 index in the present study was 3.13 ± 2.65 in the upper two/third of the squamous epithelium in the LSIL group and 19.04 ±36.40 in the HSIL group, which was statistically significant. Also, the mean Ki67 index in full thickness squamous epithelium in HSIL group was significantly higher than LSIL. The sensitivity of P16 and Ki67 index in our study was 58.73%, 66.67% and the specificity was 100% and 100%, respectively. Conclusion: Assessment of P16 expression and Ki67 index can be used to distinguish low grade (CIN1) intraepithelial lesion from high grade (CIN2/3) intraepithelial or precancerous lesions.

Dysgerminoma in a 15 years old phenotypically female Swyer syndrome with 46, XY pure gonadal dysgenesis: A case report.

Swyer syndrome is a 46, XY karyotype, with pure gonadal dysgenesis and primary amenorrhea. These females have primordial Mullerian structures and seek medical attention as they experience primary amenorrhea. Here, we report a 15-year-old girl, diagnosed as Swyer syndrome associated with left ovarian dysgerminoma.

Spontaneous Regression of Diffuse Large B-cell Lymphoma in a Patient with Ataxia-Telangiectasia.

Ataxia-telangiectasia (AT) is a type of primary immunodeficiency characterized by an autosomal recessive mode of inheritance and usually presents with progressive cerebellar ataxia in early life. This complex disease is associated with humoral and cellular immune dysfunction and other features including characteristic oculocutaneous telangiectasia and increased predisposition to cancers, particularly lymphoma and leukemia. An 11-year-old Iranian girl presented with primary immunodeficiency and was diagnosed as having AT according to her clinical manifestations and molecular findings. She had a history of two types of non-Hodgkin's lymphoma and showed spontaneous regression of her diffuse large B-cell lymphoma without any specific treatment. Gene mutations and dysfunction in patients with AT result in different manifestations including abnormal development of the thymus, immunodeficiency, increased susceptibility to malignancies, and increased radiosensitivity. No standard treatment is available for these patients. The use of immunotherapeutic strategies in patients with primary immune deficiency disease-associated tumors is potentially important.

Study of P21 Expression in Oral Lichen Planus and Oral Squamous Cell Carcinoma by Immunohistochemical Technique.

STATEMENT OF THE PROBLEM: Lichen planus is a mucocutaneous disease that is relatively common in middle aged individuals. Some studies have shown that oral lichen planus has a potential to progress to squamous cell carcinoma.p21 is a cyclin-dependent kinase inhibitor that regulates the cell cycle, thus it acts as an inhibitor in cell proliferation. PURPOSE: This study was aimed to evaluate and compare the immunostaining of p21 (as a proliferation inhibitory factor) in oral lichen planus (OLP) and oral squamous cell carcinoma (OSCC). MATERIALS AND METHOD: In this descriptive cross-sectional study, p21expression was investigated in 24 samples of oral lichen planus (OLP), 24 samples of oral squamous cell carcinoma (OSCC) and 24 samples of oral epithelial hyperplasia (OEH) by employing immunohistochemical staining. RESULTS: The mean percentage of p21-positive cells in OSCC (54.5±6.6) was significantly higher than that in OLP (32.8±6.08) and OEH (9.4±3.8). Moreover, OLP samples expressed p21 significantly higher than the OEH. Kruskal Wallis test revealed a statistically significant difference between the groups regarding the intensity of staining (p< 0.001). CONCLUSION: According to the findings of this study, the expression of p21 might be related to the potential carcinogenic transformation of lichen planus to SCC. Therefore, continuous follow-up periods for OLP are recommended for diagnosis of the malignant transformations in early stages.

Evaluation of Endoglin as an Angiogenesis Marker in Glioblastoma.

BACKGROUND AND OBJECTIVES: Angiogenesis is essential for growth and metastasis of solid malignancies. Tumor vessel count and expression of vascular endothelial growth factor (VEGF), a potent angiogenic factor, have been associated with prognosis. This study was designed to assess vessels density by using CD31 and CD105 (Endoglin) and their correlation with expression of VEGF and proliferative index (Ki67) in Glioblastoma multiforme (GBM). METHODS: We examined these parameters in GBM specimens from 50 adult patients; referred to Al-Zahra hospital Pathology Lab between 2001 to 2006.These patients did not receive pre-operative therapy. Paraffin-embedded tumor specimens were immunohistochemically stained for CD31, CD105 (Endoglin), VEGF and Ki67 (proliferation index) monoclonal antibodies. Microvessel density (MVD) was evaluated by immunostaining for CD31 and CD105.Then the results were compared between the two and also with VEGF receptors and Ki67 index. RESULTS: CD105-MVD was significantly higher in Glioblastoma compared with peritumoral normal (14.28 vs. 6.68: P=0.012). We did not find such difference for CD31. The mean of CD105-MVD was significantly higher than CD31-MVD in Glioblastoma tissue (P<0.001) although there was a significant positive relationship between them (Pearson's r=0.630 P<0.001).The VEGF scoring for tumoral tissue was 12 % (score:1), 46% (score:2) and 42% (score:3).For peritumoral normal tissue were 92% (score:1) and 8% (score:2) . So they reach to statistical significance (Chi Square, P = 0001). Both MVD of CD105 and CD31 have significant relationship with VEGF (P<0.001). CONCLUSION: We suggest that Endoglin can be used as a specific and sensitive marker for evaluation of angiogenesis in Glioblastoma.

Diagnostic value of claudin-4 marker in pleural and peritoneal effusion cytology: Does it differentiate between metastatic adenocarcinoma and reactive mesothelial cells?

BACKGROUND: Several markers have been used to make a distinction between metastatic adenocarcinoma and reactive mesothelial cells in the body cavity effusions. This study aimed to evaluate the diagnostic value of claudin-4 marker in making such a distinction. MATERIALS AND METHODS: In this cross-sectional study, a total of 92 pleural/peritoneol effusions have been studied, including 47 cases of definite metastatic carcinoma and 45 cases of reactive mesothelium, and definitely negative for malignancy. Specimens were collected from patients; cell block samples were derived and used for immunohistochemical staining. The antibody used for immunohistochemical labeling was monoclonal anti-claudin-4. In the evaluation, membrane-bound reactivity was considered as significant and positive cases were defined when at least more than 10% of tumor cells were distinctly labeled. RESULTS: Claudin-4 protein was positive in 40 specimens of metastatic carcinoma, while none of the cases of reactive mesothelium stained with the marker. This was not detected in the mesothelial cells, though. Positive staining for claudin-4 was significantly more frequent in metastatic carcinoma than in the reactive mesothelium (P > 0.0001). The sensitivity and specificity of claudin-4 to distinguish reactive mesothelium from metastatic carcinoma were 85% (95% confidence interval [CI], 71.1-93.8%) and 100% (95% CI, 91.1-100%), respectively. Furthermore, negative likelihood ratio was 0.15 (95% CI, 0.08-0.29). CONCLUSION: The results of this study demonstrated that claudin-4 is less frequently expressed in reactive mesothelium. Thus, this claudin may be helpful in differentiating metastatic carcinoma from reactive mesothelial cells in pleural and peritoneal fluid cytology specimen.

The significance of clinicopathological aspects of tumor for the detection of liver micrometastasis in patients with colorectal cancer.

BACKGROUND: Colorectal tumor is one of the main causes of death in our country. The aim of the present study was to determine the clinicopathological aspects of tumor and the presence of hepatic micrometastasis in patients with colorectal cancer (CRC). MATERIALS AND METHODS: Forty two patients with CRC were evaluated in the study surgical treatment was performed and liver biopsy was taken for the evaluation of micrometastasis by immunohistochemistry and polymerase chain reaction. The variables that have been evaluated were: Patient's gender, patients age at the time of diagnosis, size and location of tumor, tumor-node-metastasis stage and grade of the primary tumor, lymph node involvement, lymphovascular and neural invasion, presence of macrometastasis and carcinoembryonic antigen level prior to surgery. After 1 year patients were called and asked to come back to the clinic for elective colonoscopy to evaluate the surgical site for recurrence of tumor and survival. All variables were compared between patients in whom liver micrometastasis were present in comparison with patients without liver micrometastasis. RESULTS: Of the studied patients (6 with positive micrometatsis and 36 without micrometstasis), 38 were alive after 1 year (6 with positive micrometatsis and 32 without micrometstasis) and the difference was not significant between groups with or without micrometastasis (P = 0.52). In four of survived patients colonoscopy was abnormal, however this difference was not also significant between groups (P = 0.59). CONCLUSION: Clinicopathologic aspect of tumor was not different in CRC patients with and without hepatic micrometastasis.

Fatal disseminated mucormycosis in an immunocompotent patient: a case report and literature review.

Disseminated mucormycosis is a rare entity most frequently seen in neutropenic patients with hematologic malignancies, post transplants or in patients on deferoxamine therapy. We report a 64-year-old immunocompetent male with an acute pneumonia and a generalized jaundice who died within 24 h. In the autopsy, extensive perforations of spleen and multiple hemorrhage foci on the pancreas were two significant findings. Histopathological study of tissue sections revealed typical zygomycetes hyphae in the left lung, pancreas, spleen and brain. Involvement of pancreas in this patient was one of the rare features of mucormycosis reported occasionally in the literature. Our case implies an unusual clinical presentation of disseminated mucormycosis and highlights that disseminated mucormycosis should be regarded even in the immunocompetent patients.

A case of intracranial malignant fibrous histiocytoma.

We describe a case of intracranial malignant fibrous histiocytoma which had infiltrated pons, cerebellum and basal surface of left temporal lobe without any visible mass. The patient presented with a sudden loss of consciousness and vomiting. Clinical findings, laboratory tests, imaging and examination of the cerebrospinal fluid tended to establish the diagnosis of an infectious condition than a malignancy. Without any response to the antibiotics and with a progressive deterioration of neurologic and mental condition, the patient died after 20 days. In the autopsy, histological and immunohistochemical study of the brain revealed the diagnosis of malignant fibrous histiocytoma (MFH).

Determination of p53 expression in basal cell carcinoma tissues and adjacent nontumoral epidermis from sun-exposed areas of the head and neck.

BACKGROUND: This study determines the expression of P53 protein and the intensity of immunoreactivity in basal cell carcinoma in comparison with the adjacent nontumoral epidermis in sun-exposed areas of the head and neck regions. The mean age of immunoreactivity in tumoral and adjacent nontumoral epidermis is also determined. METHODS: This descriptive-analytical study was performed retrospectively over a 5-year period on 150 basal cell carcinoma cases in the Pathology Department of Alzahra Hospital in Isfahan. Proper quality paraffin blocks were chosen for immunohistochemical staining for P53 through the immunoperoxidase method. The intensity of immunoreactivity was graded. The age of the patients was also recorded. RESULTS: Positive P53 immunoreactivity was observed in 123 basal cell carcinoma tissues (82%) and in 117 adjacent nontumoral epidermis (78%) (P = 0.38). The frequency of severe immunoreactivity in tumoral tissue and in adjacent nontumoral epidermis was 46% and 32%, respectively (P = 0.046). The mean age of P53 expression was 66.2 years for tumoral tissue and 66.1 years for nontumoral epidermis. The mean age of those who did not express P53 was 52.6 and 55.9 years for the tumoral and nontumoral epidermis, respectively (P < 0.001). CONCLUSION: No significant difference was detected between P53 immunoreactivity in tumoral tissue and adjacent nontumoral epidermis. Intensity of P53 immunoreactivity was greater in tumoral specimens. Comparison of mean ages showed a significant difference between P53-expressing and non-P53-expressing groups.